Navigation Links
Cancer drug brings relief to patients of Crohn’s Diseas

Researchers have discovered that the use of the drug sargramostim,// also known as Leukine, have helped the patients of Crohn’s disease recover totally from their symptoms. The drug sargramostim is generally used for treating cancer patients who are going through chemotherapy.

Crohn’s disease is the condition that causes inflammation of the small intestine. This can cause pain and diarrhea. It is difficult to diagnose, as its symptoms are similar to other intestinal disorders like irritable bowel syndrome etc. this condition may run in families. The condition is also called ileitis or enteritis.

The drug sargramostim is typically used to increase the recovery of the white blood cells that may drop during the chemotherapy administered to treat patients suffering from cancer. The drug helps the patient gain in immunity to fight outside germs.

Traditionally it is believed that Crohn’s disease is an over activation of the immune system and treatment comprised of giving medication to the patients that will suppress immunity. With the new treatment, there seems to be a total turn in the opposite direction of not lowering but increasing the immune system and allow the body to fight its own battls.
'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2Skill Without a Question Luck Maybe a Bit Y E Yang Winning the War Between His Ears Absolutely 54608 1Skill Without a Question Luck Maybe a Bit Y E Yang Winning the War Between His Ears Absolutely 54608 2Skill Without a Question Luck Maybe a Bit Y E Yang Winning the War Between His Ears Absolutely 54608 3Career Step Partners with SUNY Orange County Community College to Help Students Gain Careers in Growing Healthcare Industry 54604 1Career Step Partners with SUNY Orange County Community College to Help Students Gain Careers in Growing Healthcare Industry 54604 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 1AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 7